Welcome back,

CONFERENCE UPDATE

ESGO 2024

The European Society of Gynaecological Oncology (ESGO) 2024 Congress

March 7-10, 2024 |

Barcelona, Spain

2024

Improved prediction of PARPi responders in ovarian cancer patients using the Leuven PARPi benefit test

OBSTETRICS & GYNECOLOGY
|
ONCOLOGY

13 May 2024
Long-term HRQoL outcomes of dostarlimab + chemotherapy in patients with primary advanced or recurrent EC from the RUBY trial

OBSTETRICS & GYNECOLOGY
|
ONCOLOGY

8 May 2024
Investigating the association between pretreatment thrombocytosis and ovarian cancer recurrence and survival

OBSTETRICS & GYNECOLOGY
|
ONCOLOGY

8 May 2024
Mechanisms of ADC resistance and methods to overcome resistance

OBSTETRICS & GYNECOLOGY
|
ONCOLOGY

8 May 2024
Final analysis of NORA demonstrates the OS benefits of niraparib maintenance in Chinese PSROC patients regardless of gBRCAm status

OBSTETRICS & GYNECOLOGY
|
ONCOLOGY

8 May 2024
HRQoL improvements with pembrolizumab + CCRT and EBRT in high-risk LACC patients in ENGOT-CX11/GOG-3047/KEYNOTE A18

OBSTETRICS & GYNECOLOGY
|
ONCOLOGY

29 Apr 2024
Validating PFS as a surrogate marker for OS in endometrial cancer treatment assessment: Results from an EORTC-YGCG systemic review

OBSTETRICS & GYNECOLOGY
|
ONCOLOGY

26 Apr 2024
Integration of molecular classification in the 2023 FIGO staging forprognostic refinement in endometrial cancer

OBSTETRICS & GYNECOLOGY
|
ONCOLOGY

26 Apr 2024

eaa0190a-4510-467f-900f-c94c7b668484